Stay updated on TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial
Sign up to get notified when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.

Latest updates to the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This reflects an update to the page’s revision tag rather than substantive changes to study data or content.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, indicating a minor page maintenance or documentation update rather than changes to study details.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision: v3.5.2 was added in the page footer, replacing Revision: v3.5.0.SummaryDifference0.0%

- Check58 days agoChange DetectedAdded publication: Grimm MO et al., Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024;10(6):755-764. Removed Erratum for the same article (JAMA Oncol. 2024 Nov 1;10(11):1598).SummaryDifference0.0%

- Check72 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.3 added and Revision: v3.4.2 removed. This change does not alter core study information or user actions.SummaryDifference0.0%

Stay in the know with updates to TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TITAN-TCC Nivolumab Tailored Immunotherapy Clinical Trial page.